Search Results - "Zwillich, Samuel H"

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis by Fleischmann, Roy, Kremer, Joel, Cush, John, Schulze-Koops, Hendrik, Connell, Carol A, Bradley, John D, Gruben, David, Wallenstein, Gene V, Zwillich, Samuel H, Kanik, Keith S

“…In a placebo-controlled trial, monotherapy with tofacitinib, an oral Janus kinase inhibitor, reduced the symptoms and signs of rheumatoid arthritis. Adverse…”
Get full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial by Burmester, Gerd R, Prof, Blanco, Ricardo, MD, Charles-Schoeman, Christina, MD, Wollenhaupt, Jürgen, Prof, Zerbini, Cristiano, MD, Benda, Birgitta, MD, Gruben, David, PhD, Wallenstein, Gene, PhD, Krishnaswami, Sriram, PhD, Zwillich, Samuel H, MD, Koncz, Tamas, MD, Soma, Koshika, MD, Bradley, John, MD, Mebus, Charles, PhD

“…Summary Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently…”
Get full text

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies by WOLLENHAUPT, Jürgen, SILVERFIELD, Joel, KOMURO, Yoshihiro, ZWILLICH, Samuel H, LISY WANG, RIESE, Richard J, EUN BONG LEE, CURTIS, Jeffrey R, WOOD, Susan P, SOMA, Koshika, NDUAKA, Chudy I, BENDA, Birgitta, GRUBEN, David, NAKAMURA, Hiroyuki

“…To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA). Data were pooled from…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis by Vieira, Maria-Cecilia, PhD, Zwillich, Samuel H., MD, Jansen, Jeroen P., PhD, Smiechowski, Brielan, MSc, Spurden, Dean, PhD, Wallenstein, Gene V., MD

“…Abstract Purpose Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety…”
Get full text

Therapeutic targeting of Janus kinases by Pesu, Marko, Laurence, Arian, Kishore, Nandini, Zwillich, Samuel H., Chan, Gary, O'Shea, John J.

“…Summary Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such…”
Get full text

CCR1 antagonists: what have we learned from clinical trials by Gladue, Ronald P, Brown, Matthew F, Zwillich, Samuel H

“…The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on…”
Get more information

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database by George, Prethibha, Jagun, Oladayo, Liu, Qing, Wentworth, Charles, Napatalung, Lynne, Wolk, Robert, Anway, Susan, Zwillich, Samuel H.

“…Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids…”
Get full text

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016 by Sørensen, Sissel Brandt Toft, George, Prethibha, Jagun, Oladayo, Wolk, Robert, Napatalung, Lynne, Zwillich, Samuel H., Iversen, Lars, Ehrenstein, Vera

“…Introduction Alopecia areata (AA) is an autoimmune skin disease presenting as nonscarring hair loss. Information on the epidemiology of AA, especially the…”
Get full text

Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data by Takeuchi, Tsutomu, Yamanaka, Hisashi, Yamaoka, Kunihiro, Arai, Shoko, Toyoizumi, Shigeyuki, DeMasi, Ryan, Fukuma, Yuri, Hirose, Tomohiro, Sugiyama, Naonobu, Zwillich, Samuel H., Tanaka, Yoshiya

“…Objectives: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We investigated concomitant methotrexate (MTX) dose on…”
Get full text

A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata by Anderson, Samira, Cavaletti, Guido, Hood, Linda J., Polydefkis, Michael, Herrmann, David N., Rance, Gary, King, Brett, McMichael, Amy J., Senna, Maryanne M., Kim, Brian S., Napatalung, Lynne, Wolk, Robert, Zwillich, Samuel H., Schaefer, Gregor, Gong, Yankun, Sisson, Melanie, Posner, Holly B.

“…Reversible axonal swelling and brainstem auditory evoked potential (BAEP) changes were observed in standard chronic (9‐month) toxicology studies in dogs…”
Get full text

Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis by Tanaka, Yoshiya, Zwillich, Samuel H.

Get full text

Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate by Tanaka, Yoshiya, Suzuki, Makoto, Nakamura, Hiroyuki, Toyoizumi, Shigeyuki, Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 4 doses of oral tofacitinib (CP‐690,550) with placebo in Japanese patients with active…”
Get full text

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial by KREMER, Joel, LI, Zhan-Guo, ZWILLICH, Samuel H, KONCZ, Tamas, RIESE, Richard, BRADLEY, John, HALL, Stephen, FLEISCHMANN, Roy, GENOVESE, Mark, MARTIN-MOLA, Emilio, ISAACS, John D, GRUBEN, David, WALLENSTEIN, Gene, KRISHNASWAMI, Sriram

“…Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a…”
Get full text

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial by King, Brett, Zhang, Xingqi, Harcha, Walter Gubelin, Szepietowski, Jacek C, Shapiro, Jerry, Lynde, Charles, Mesinkovska, Natasha A, Zwillich, Samuel H, Napatalung, Lynne, Wajsbrot, Dalia, Fayyad, Rana, Freyman, Amy, Mitra, Debanjali, Purohit, Vivek, Sinclair, Rodney, Wolk, Robert

“…Alopecia areata is characterised by non-scarring loss of scalp, face, or body hair. We investigated the efficacy and safety of ritlecitinib, an oral, selective…”
Get full text

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study by van der Heijde, Désirée, Tanaka, Yoshiya, Fleischmann, Roy, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano, Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Wyman, Bradley T., Gruben, David, Benda, Birgitta, Wallenstein, Gene, Krishnaswami, Sriram, Zwillich, Samuel H., Bradley, John D., Connell, Carol A.

“…Objective The purpose of this 24‐month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with…”
Get full text

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs by Fleischmann, Roy, Cutolo, Maurizio, Genovese, Mark C., Lee, Eun Bong, Kanik, Keith S., Sadis, Seth, Connell, Carol A., Gruben, David, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie E., Zwillich, Samuel H.

“…Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550) or adalimumab monotherapy with placebo for the…”
Get full text

Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review by Mostaghimi, Arash, Napatalung, Lynne, Sikirica, Vanja, Winnette, Randall, Xenakis, Jason, Zwillich, Samuel H., Gorsh, Boris

“…Introduction Alopecia areata (AA) is a chronic, autoimmune disease of hair loss, which can significantly affect the emotional and psychological well-being of…”
Get full text

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria by Smolen, Josef S., Aletaha, Daniel, Gruben, David, Zwillich, Samuel H., Krishnaswami, Sriram, Mebus, Charles

“…Objective Tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA). In previous clinical trials of tofacitinib, a…”
Get full text